SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

The SPDR Gold Shares ETF (GLD) is experiencing a sharp sell-off as a strengthening dollar and rising Treasury yields trigger a wave of liquidation among investors who previously viewed the asset as a safe haven. Community sentiment is deeply divided, with many traders frustrated by the lack of defensive performance during geopolitical instability, while others advocate for long-term accumulation as they believe current price levels represent a significant opportunity before potential future volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing intense volatility as investors weigh the fallout of a federal indictment involving a co-founder and employees accused of smuggling AI technology to China, while the company maintains it was a victim of deception. The community is deeply divided between bargain-hunting bulls who see a buying opportunity in the stock's massive sell-off and bearish traders who fear further regulatory crackdowns, potential delisting, and the erosion of corporate trust.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is surging as geopolitical instability in the Persian Gulf sparks critical supply chain concerns, with traders betting on the firm's role in European energy security following significant infrastructure disruptions. The community is intensely focused on the stock's potential for a multi-day rally, with many active traders debating the impact of the ongoing conflict on natural gas prices and debating whether to hold or lock in gains during this period of high volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and community debate following news of the company's joint semiconductor venture with SpaceX, while investors simultaneously react to a legal verdict finding Elon Musk liable for misleading Twitter shareholders. The stock is seeing polarized discussion as market participants weigh these high-stakes infrastructure ambitions against ongoing concerns regarding delivery growth, the company's high valuation, and broader macroeconomic volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The market is experiencing significant volatility and uncertainty as traders react to a high-stakes geopolitical standoff in the Middle East, specifically a deadline regarding the Strait of Hormuz. Community discussion is heavily divided between bears betting on a deeper downturn driven by energy supply fears and recessionary concerns, and bulls attempting to buy the dip in anticipation of a potential ceasefire or market recovery.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the significant supply disruptions to global natural gas infrastructure against the company's aggressive expansion and capacity to leverage spot market pricing. The community remains highly focused on potential short squeeze setups and the long-term impact of regional geopolitical instability on LNG energy prices.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining is gaining investor attention as the community weighs strong production growth and high profit margins against the geopolitical risks associated with its Zimbabwe-based operations. Discussions are heavily focused on the potential of the Bilboes project to scale production, alongside recent corporate developments like BlackRock increasing its stake and the company's strategic decision to sell its solar assets to fund further expansion.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened community debate as investors weigh the project's long-term technical potential against its recent price volatility and market underperformance. While some retail participants continue to accumulate shares based on long-term project milestones, others are actively exiting and voicing frustration over the lack of consistent momentum compared to the broader crypto market.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is experiencing significant downward pressure as investors pivot toward risk-off sentiment, driven by persistent inflation concerns and fears of a systemic credit shock tied to surging energy prices. Community discussion is heavily focused on the bond market signaling a long-term inflationary regime, with many traders debating whether current yields offer a compelling entry point for capital preservation versus the risk of further volatility.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing heightened volatility as investors weigh President Trump's 48-hour ultimatum against Iran and the potential for a significant escalation in Middle East tensions. Community discussions are centered on the impact of surging oil prices, bond market fluctuations, and potential threats to global energy infrastructure, with traders debating whether these geopolitical risks are already priced into the index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seth Lederman Purchases 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, for a total transaction of $223,350.00. Following...

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following...

Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Noble Financial upped their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on...

<ul class="summary-bullets"><li>CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization.</li><li>Investors are also watching TNX-4800, with the company planning FDA talks on Phase 2/3 development and potential studies beginning in 2027-2028.</li><li>Tonix posted a net loss of $46.9 million in Q4, compared with a net loss of $22.1 million a year ago.</li></ul><p>Shares of Tonix Pharmaceuticals (TNXP) rose over 1% in premarket trading on Friday as investors cheered early prescription traction for its fibromyalgia drug Tonmya and growing interest in its Lyme disease prevention program, despite a wider quarterly loss.</p><p><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is headed for its seventh straight week of losses and has declined 0.3% so far this week.</p><h2 class="st-heading-2"><strong>Tonmya Launch Gains Early Prescriber Traction</strong></h2><p>Tonix said Tonmya, approved by the U.S. Food and Drug Administration (FDA) in August 2025 for fibromyalgia in adults, is showing early adoption after its Nov.17, 2025, commercial launch. The therapy is the first new prescription medicine approved for fibromyalgia in more than 15 years.</p><p>Through Feb.27, more than 1,500 healthcare providers had prescribed Tonmya, about 2,500 patients had initiated treatment and cumulative prescriptions reached nearly 4,200, including bridge prescriptions provided through the company’s specialty pharmacy channel.</p><p>“Early prescription trends reflect favorable prescriber uptake and repeat utilization consistent with our internal launch expectations,” CEO Seth Lederman said in a statement. Tonix has established distribution through wholesalers, specialty pharmacies, and patient support programs, including copay assistance and prior authorization services.</p><p>Speaking at the Life Sciences Virtual Investor Forum on Wednesday, Lederman said early anecdotal feedback suggests patients are reporting positive results and that prescribing is occurring across multiple specialties, including rheumatology, primary care, pain management and neurology.</p><h2 class="st-heading-2"><strong>Lyme Disease Prevention Drug In Focus</strong></h2><p>Investors have also been paying attention to TNX-4800, a long-acting monoclonal antibody for the seasonal prevention of Lyme disease, an area with no FDA-approved vaccines or prophylactic treatments currently available.</p><p>Tonix plans to meet with the FDA this year to discuss Phase 2/3 development options, including a field study and a controlled human infection model study. The company expects investigational products to be available in early 2027, with a U.S. field study potentially beginning in 2027 and a human challenge study planned for 2028.</p><h2 class="st-heading-2"><strong>TNXP Q4 Review</strong></h2><p>Tonix reported fourth-quarter (Q4) revenue of about $534 million, significantly up from $2.6 million a year earlier. However, the company posted a net loss of $46.9 million, or $3.98 per share, compared with a net loss of $22.1 million, or $9.77 per share, in the same period a year ago.</p><p>Tonix ended 2025 with $207.6 million in cash and cash equivalents, which will fund operations into the first quarter of 2027.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for TNXP was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/tnxp_ss_png_63ee8c6e92.webp" alt="tnxp ss.png" width="969" height="141"><figcaption>TNXP sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/curiousturtle2000/message/647416946">called</a> Tonix’s latest&nbsp;earnings report “very encouraging.”</p><p><stembedurl>https://stocktwits.com/curiousturtle2000/message/647416946</stembedurl></p><p>Another user&nbsp;<a href="https://stocktwits.com/StockJayC/message/647411678">said</a>, “$20m-$25m cash burn = 2 years continuing at the current burn with no change to operations or factoring revenue increases,” adding that they expect the stock to rise over $60 by June.&nbsp;</p><p><stembedurl>https://stocktwits.com/StockJayC/message/647411678</stembedurl></p><p>TNXP stock has declined 14% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print

Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.

Equity

Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing the consensus estimate of ($3.16) by...

Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul><p>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.</p><p>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.</p><h2 class="st-heading-2">What Is Lyme Disease?</h2><p>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.</p><p>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.</p><h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2><p>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</p><p>“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.</p><h2 class="st-heading-2">Registered Direct Offering</h2><p>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.</p><p>A Stocktwits user sounded optimistic about the stock.</p><p><stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl></p><p><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

$TNXP Q4 &#39;25 Earnings Results &amp; Recap

Tonix Pharmaceuticals Holding Corp. reported net product revenue of $13.1M in 2025, an increase from $10.1M in 2024, with a net loss of $124M in 2025, an improvement from $130M in 2024.

Stocktwits

Tonix Pharmaceuticals Holding Corp

 Q4 '25 Earnings Results & Recap

Tonix Pharmaceuticals Holding Corp. reported net product revenue of $13.1M in 2025, an increase from $10.1M in 2024, with a net loss of $124M in 2025, an improvement from $130M in 2024.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp